Previous 10 | Next 10 |
home / stock / cslly / cslly news
2024-02-13 00:53:08 ET CSL Ltd (CSLLY) Q2 2024 Earnings Conference Call February 12, 2024, 19:00 ET Company Participants Mark Dehring - Head, IR Paul McKenzie - MD, CEO & Executive Director William Mezzanotte - EVP & Head, Research and Development Her...
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ Canada NewsWire Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS 4 Revenue $8.05 billion , up 11% at CC 3 NPAT $1.90 billion 1 ...
2024-02-12 13:53:40 ET More on CSL CSL Limited: Positive Capital Return And Earnings Growth Expectations Arcturus, CSL win approval for world’s first self-amplifying mRNA vaccine in Japan Historical earnings data for CSL Dividend scorecard for CSL ...
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) PR Newswire KING OF PRUSSIA, Pa. , Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today ...
2024-02-10 17:35:58 ET Major earnings expected after the bell on Monday include: Waste Management ( WM ) Arista Networks ( ANET ) Federal Realty Investment Trust ( FRT ) Star Bulk Carriers Corp. ( SBLK ) Cadence Design Systems ( CDNS ) Read ...
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Short communication follows previou...
2024-01-31 17:20:05 ET Summary Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 bill...
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options PR Newswire Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to pati...
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
2024-01-03 10:19:29 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Drugmakers reportedly planning to raise p...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in...
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...